[1]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,(08):131-133.[doi:10.3969/j.issn.1006-1959.2018.08.044]
 HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,(08):131-133.[doi:10.3969/j.issn.1006-1959.2018.08.044]
点击复制

螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年08期
页码:
131-133
栏目:
药物与临床
出版日期:
2018-04-15

文章信息/Info

Title:
Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure
文章编号:
1006-1959(2018)08-0131-03
作者:
胡丽君
德阳市人民医院心血管内科,四川 德阳 618000
Author(s):
HU Li-jun
Department of Cardiovascular Medicine,Deyang People's Hospital,Deyang 618000,Sichuan,China
关键词:
螺内酯曲美他嗪心力衰竭远期预后
Keywords:
Key words:SpironolactoneTrimetazidineHeart failureLong-term prognosis
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2018.08.044
文献标志码:
A
摘要:
目的 探讨螺内酯联合曲美他治疗善慢性心力衰竭患者的远期预后疗效及其改善患者心功能的作用。方法 选取2016年2月~2016年8月我院收治的CHF患者86例为研究对象,随机分为观察组和对照组,各43例,对照组予常规抗心衰治疗,观察组在常规抗心衰治疗基础上加用螺内酯20 mg/d联合曲美他嗪20 mg tid服12个月,观察治疗前后两组患者左室射血分数(LVEF)、6 min步行试验(6MWD)、NYHA心功能分级、左室结构功能指标及BNP变化水平。结果 治疗后NYHA心功能分级比较观察组优于对照组,差异有统计学意义(P<0.05);治疗后观察组LVEF、6MWD较对照组有明显升高,BNP较对照组下降明显,差异有统计学意义(P<0.05);治疗后观察组LVESD及LVEDD较对照组有明显缩短,LVESV较对照组有明显降低,差异均有统计学意义(P<0.05)。结论 对慢性心力衰竭患者加用螺内酯联合曲美他嗪治疗,能够改善患者临床症状和心功能,同时改善患者左室结构和功能及远期预后,值得推广。
Abstract:
Abstract:Objective To investigate the long-term prognosis of spironolactone combined with trimetazol in the treatment of chronic heart failure(CHF)and the effect of improving cardiac function.Methods From February 2016 to August 2016,86 patients with CHF were randomly divided into two groups: observation group(n=43)and control group(n=43).The control group was treated with routine anti-heart failure therapy,the observation group was treated with spironolactone 20 mg/d combined with trimetazidine 20 mg tid for 12 months.The left ventricular ejection fraction(LVEF)and left ventricular ejection fraction(LVEF)of 6 min walking test were measured before and after treatment as well as the index of left ventricular structure and function and the level of BNP.Results After treatment, the NYHA cardiac function grading in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the LVEF and 6MWD levels in the observation group were significantly higher than those in the control group,and BNP was significantly lower than that in the control group,the difference was statistically significant(P< 0.05).After treatment,the LVESD and LVEDD in the observation group were significantly shorter than those in the control group,and the LVESV was significantly lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion The addition of spironolactone combined with trimetazidine to patients with chronic heart failure can improve clinical symptoms and heart function,improve left ventricular structure and function,and improve long-term prognosis.It is worth promoting.

参考文献/References:

[1]McMurray JJ,Adamopoulos S,Anker SD,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012[J].Eur J Heart Fail,2012,14(8):803-869.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[3]戚玮琳,李勇.醛固酮受体拮抗剂-心力衰竭药物治疗的新纪元[J].世界临床药物,2011,32(11):655-658.
[4]张建明.螺内酯对慢性心力衰竭患者治疗的远期预后的影响[J].中西医结合心血管病电子杂志,2016,4(24):53-54.
[5]李含蓄.螺内酯在慢性充血性心力衰竭治疗中的应用[J].当代医学,2017,23(8):120-121.
[6]侯晓林.曲美他嗪对老年慢性心力衰竭患者心功能及心率变异性的影响[J].实用医院临床杂志,2017,5(14):56-58.

相似文献/References:

[1]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
 WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Medical Information,2018,(08):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[2]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
 HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,(08):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[3]岳卫东.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究[J].医学信息,2018,(21):141.[doi:10.3969/j.issn.1006-1959.2018.21.040]
 YUE Wei-dong.Clinical Study of Trimetazidine Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Angina Pectoris with Dyslipidemia[J].Medical Information,2018,(08):141.[doi:10.3969/j.issn.1006-1959.2018.21.040]
[4]宫慧超,王 辉,刘迎午.尼可地尔联合曲美他嗪在不稳定心绞痛患者中应用的临床研究[J].医学信息,2019,(07):148.[doi:10.3969/j.issn.1006-1959.2019.07.045]
 GONG Hui-chao,WANG Hui,LIU Ying-wu.Clinical Study of Nicorandil Combined with Trimetazidine in Patients with Unstable Angina Pectoris[J].Medical Information,2019,(08):148.[doi:10.3969/j.issn.1006-1959.2019.07.045]
[5]张文航.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴 血脂异常的临床疗效[J].医学信息,2019,(18):144.[doi:10.3969/j.issn.1006-1959.2019.18.049]
 ZHANG Wen-hang.Clinical Efficacy of Trimetazidine Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Angina Pectoris with Dyslipidemia[J].Medical Information,2019,(08):144.[doi:10.3969/j.issn.1006-1959.2019.18.049]
[6]纪东华.曲美他嗪治疗老年冠心病心力衰竭的疗效及其对患者 炎症因子的影响[J].医学信息,2019,(13):141.[doi:10.3969/j.issn.1006-1959.2019.13.043]
 JI Dong-hua.Efficacy of Trimetazidine in the Treatment of Elderly Patients with Coronary Heart Disease and Its Effect on Inflammatory Factors[J].Medical Information,2019,(08):141.[doi:10.3969/j.issn.1006-1959.2019.13.043]

更新日期/Last Update: 2018-04-15